Cystic Fibrosis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Cystic Fibrosis – Drugs In Development, 2023’, provides an overview of the Cystic Fibrosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis
- The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cystic Fibrosis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
4D Molecular Therapeutics IncAbbVie Inc
Aeon Respire Inc
AeroNeph Therapeutics Inc
Airway Therapeutics Inc
Alteron Therapeutics LLC
Anoat Therapeutics
Arcturus Therapeutics Holdings Inc
Aridis Pharmaceuticals Inc
Armata Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc
Atlantic Healthcare Plc
Avidin Biotechnology Ltd
Biofilm Pharma
BiomX Inc
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Branca Bunus Ltd
Carbon Biosciences Inc
Carmine Therapeutics Inc
Chiesi Farmaceutici SpA
ContraFect Corp
CRISPR Therapeutics AG
Cystetic Medicines Inc
Dartmouth College
Destiny Pharma Plc
Eldec Pharmaceuticals Inc
Eloxx Pharmaceuticals Inc
EmphyCorp Inc
Ensysce Biosciences Inc
Enterprise Therapeutics Ltd
Evotec SE
F. Hoffmann-La Roche Ltd
Felix Biotechnology Inc
GeneToBe LLC
Gensaic Inc
George Washington University
Helperby Therapeutics Group Ltd
Hunterian Medicine LLC
ImmunoForge Co Ltd
Insmed Inc
Israel Institute of Technology
Kantify
Kineta Inc
Kither Biotech Srl
Krystal Biotech Inc
Laurent Pharmaceuticals Inc
Loxegen Pty Ltd
MannKind Corp
MD Healthcare Inc
Metagenomi Inc
Microbion Corp
Moderna Inc
Nabriva Therapeutics Plc
NuPeak Therapeutics Inc
Nuravax Inc
Omnispirant Ltd
Oregon State University
OrPro Therapeutics Inc
Peptilogics Inc
Porosome Therapeutics Inc
Prime Medicine Inc
Prolong Pharmaceuticals LLC
PureIMS BV
Pylum Biosciences Inc
RAGE Biotech Pty Ltd
Rare Partners Srl
Recode Therapeutics Inc
Respirion Pharmaceuticals Pty Ltd
RS BioTherapeutics Inc
Saliogen Therapeutics Inc
SciClone Pharmaceuticals Holdings Ltd
Sionna Therapeutics Inc
SOLA Biosciences LLC
Southern Research Institute
Specific Biologics Inc
Spexis AG
Spirovant Sciences Inc
SpliSense Ltd
Synovo GmbH
Tavanta Therapeutics Inc
Telum Therapeutics SL
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
Thirty Respiratory Ltd
UAB Minority Health and Health Equity Research Center
University of Barcelona
University of Maryland
University of North Carolina
University of Southampton
University of Wollongong
Vast Therapeutics Inc
Verona Pharma Plc
Vertex Pharmaceuticals Inc
VGSK Technologies Inc
Vironika LLC
Windtree Therapeutics Inc
Xellia Pharmaceuticals ApS
Zambon Co SpA
Zata Pharmaceuticals Inc
Ziphius Vaccines NV